Ailux Teams with Lilly to Accelerate AI Antibody Development
Ailux, an innovator in AI-powered biologics and a completely owned subsidiary of XtalPi (2228.HK), a world chief in AI drug discovery, right this moment introduced a strategic platform-based collaboration with Eli Lilly and Company (“Lilly”) to speed up the invention and growth of bispecific antibodies for the remedy of varied illnesses. Through this collaboration, Lilly…
